Experimental drug shown to 'significantly' slow progression of brain cancer
A new experimental drug was found to "significantly" reduce the progression of brain cancer, Reuters reported.
Vorasidenib, created by Servier Group, a private drug developer, was shown to slow the progression of brain tumors by an average of over 16 months, per Bloomberg. The results of the 331-patient study were published June 4 in The New England Journal of Medicine.
The study's lead author, Ingo Mellinghoff, described this as "a very big finding," adding that the drug "is the first molecularly targeted treatment for diffuse glioma." Vorasidenib specifically works on Grade 2 gliomas, which are "progressive, malignant brain tumors" that are "more common in adults but can also occur in children and teenagers," according to Reuters. The drug blocks a specific enzyme mutated in low-grade gliomas, keeping them from progressing and postponing the need for further treatment like chemotherapy.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"What you just heard is a trial that was well done and well thought out: to use an oral, targeted, well-tolerated therapy to see if we could delay the use of our standard chemotherapy and radiation," Wake Forest Baptist Health's Dr. Glenn Lesser commented at an American Society of Clinical Oncology briefing. "The results are quite striking and they're statistically highly significant, and more importantly, they're clinically very, very significant."
Servier Group is working to get the drug approved by the Food & Drug Administration for use in the U.S.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
The alarming rise of cancer in young people
Under the radar Cancer rates are rising, and the cause is not clear
By Devika Rao, The Week US Published
-
How happy is Finland really?
Today's Big Question Nordic nation tops global happiness survey for seventh year in a row with 'focus on contentment over joy'
By Harriet Marsden, The Week UK Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Our microbiome is social like us
The Explainer Microbes can be friendly too
By Devika Rao, The Week US Published
-
What Florida is — and isn't — doing to curb the biggest measles outbreak in the US
Talking Points DeSantis appointee defies expert consensus to stop the spread
By Joel Mathis, The Week US Published
-
How love impacts your health
The Explainer Turns out you actually can die of a broken heart
By Devika Rao, The Week US Published
-
The race to develop male birth control
The Explainer New contraception is being conceived
By Devika Rao, The Week US Published
-
Syphilis cases are on the rise in the US
The explainer The STI is spiking in all demographics
By Devika Rao, The Week US Published